• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ImmunityBio, Inc. - Common Stock (NQ:IBRX)

    6.960 -0.330 (-4.53%)
    Official Closing Price Updated: 4:15 PM EDT, Apr 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 10,876,051
    Open 7.250
    Bid (Size) 6.980 (100)
    Ask (Size) 7.040 (700)
    Prev. Close 7.290
    Today's Range 6.920 - 7.270
    52wk Range 1.830 - 12.43
    Shares Outstanding 391,156,513
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Fraud Lawsuit
    News headline image
    ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
    Did you buy IBRX securities between January 19, 2026, and March 24, 2026? 
    Via TheNewswire.com
    Topics Fraud Lawsuit

    Performance

    YTD
    +244.6%
    +244.6%
    1 Month
    +4.5%
    +4.5%
    3 Month
    +12.1%
    +12.1%
    6 Month
    +161.7%
    +161.7%
    1 Year
    +164.6%
    +164.6%

    More News

    Read More
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    ImmunityBio, Inc. (IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit
    Via NewMediaWire
    Topics Fraud Lawsuit
    News headline image
    ImmunityBio, Inc. (IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit
    Via TheNewswire.com
    Topics Fraud Lawsuit
    News headline image
    ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit
    Via NewMediaWire
    Topics Fraud Lawsuit
    News headline image
    ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit
    Via TheNewswire.com
    Topics Fraud Lawsuit
    News headline image
    IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    ImmunityBio, Inc. (IBRX) Securities Fraud Class Action Lawsuit Filed; May 26, 2026, Lead Plaintiff Deadline
    Via NewMediaWire
    Topics Fraud Lawsuit
    News headline image
    ImmunityBio, Inc. (IBRX) Securities Fraud Class Action Lawsuit Filed; May 26, 2026, Lead Plaintiff Deadline
    Via TheNewswire.com
    Topics Fraud Lawsuit
    News headline image
    ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
    From SkyMedia, LLC
    Via GlobeNewswire
    News headline image
    SHAREHOLDER ALERT Bernstein Liebhard LLP Securities Class Action Lawsuit Filed Against ImmunityBio, Inc. (IBRX)
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    ImmunityBio, Inc. (IBRX) Class Action Lawsuit: Investors Face May 26, 2026, Deadline
    Via NewMediaWire
    Topics Fraud Lawsuit
    News headline image
    ImmunityBio, Inc. (IBRX) Class Action Lawsuit: Investors Face May 26, 2026, Deadline
    Via TheNewswire.com
    Topics Fraud Lawsuit
    News headline image
    ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
    From Kahn Swick & Foti, LLC
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    ImmunityBio Stock Rises As ANKTIVA Launches in Saudi Arabia ↗
    Via Benzinga
    News headline image
    SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    Deadline Approaching for Investors of ImmunityBio, Inc. (NASDAQ: IBRX) - Contact Kaplan Fox Before May 26, 2026
    Via NewMediaWire
    Topics Lawsuit
    News headline image
    Deadline Approaching for Investors of ImmunityBio, Inc. (NASDAQ: IBRX) - Contact Kaplan Fox Before May 26, 2026
    Via TheNewswire.com
    Topics Lawsuit

    Frequently Asked Questions

    Is ImmunityBio, Inc. - Common Stock publicly traded?
    Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
    What exchange does ImmunityBio, Inc. - Common Stock trade on?
    ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
    The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
    What is the current price of ImmunityBio, Inc. - Common Stock?
    The current price of ImmunityBio, Inc. - Common Stock is 6.960
    When was ImmunityBio, Inc. - Common Stock last traded?
    The last trade of ImmunityBio, Inc. - Common Stock was at 04/28/26 04:15 PM ET
    What is the market capitalization of ImmunityBio, Inc. - Common Stock?
    The market capitalization of ImmunityBio, Inc. - Common Stock is 2.72B
    How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
    ImmunityBio, Inc. - Common Stock has 3B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.